Sorafenib, a standard first-line treatment option for HCC, is known to affect the activity of a broad spectrum of kinases, but has little effect on the activity of the PI3K-Akt-Tor signaling, a pathway that, as recently proposed26,27, might represent a mechanism of acquired resistance to this agent. Here, AKT1 is linked to hepatocellular carcinoma.